Latest research on Sertraline

Sertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Sertraline may be used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (social phobia).

Latest findings

The antidepressant types were divided into three categories: i) selective serotonin reuptake inhibitors including Citalopram, esCitalopram, fluoxetine, Paroxetine, and Sertraline, ii) newer antidepressants such as Bupropion, Venlafaxine, and Mirtazapine, and iii) older anti-depressants such as Amitriptyline, Clomipramine, Imipramine, Milnacipran, Nortriptyline, tianeptine, and Trazodone. [source, 2016]
The most common SSRIs prescribed at baseline were Paroxetine (29.3%), fluoxetine (23.6%), Escitalopram (20.0%), and Sertraline (12.9%). [source, 2016]
The median daily doses of these medications at baseline were 20.0 mg/day for Paroxetine, 10.0 mg/day for Escitalopram, 50.0 mg/day for Sertraline, 20.0 mg/day for fluoxetine, and 60.0 mg/day for Duloxetine. [source, 2016]
The patients included in this maintenance phase were those identified as responders at the end of prior 16-week continuous treatment with the SSRI Sertraline. [source, 2016]
While long-term treatment with Sertraline resulted in only modest additional improvement of psychosocial functioning over that achieved in the short-term phase, those taking placebo experienced substantial worsening in psychosocial functioning compared to those taking Sertraline during the maintenance phase. [source, 2016]
Additional covariate information regarding age, gender, marital status, education levels, family size, house possession, disease history, current use of anti-depressants medications (including Nortriptyline, Amitriptyline or Imipramine, fluoxetine, Citalopram, Fluvoxamine and Sertraline) and dietary supplements (including intake of iron, Calcium, vitamins and other dietary supplements) was obtained using self-administered questionnaires. [source, 2016]
Although two SNRIs (Milnacipran and Duloxetine) and four selective serotonin reuptake inhibitors (Fluvoxamine, Paroxetine, Sertraline, and Escitalopram) have been approved in Japan as of August 2015, the maximum dosages for most of these are considerably lower than those used in western countries on the basis of balance between the benefits and risks in the Japanese population. [source, 2016]
For example, the maximum dosages approved in the US and Japan, respectively, for the treatment of MDD are as follows: Milnacipran (200 mg/100 mg), Duloxetine (120 mg/60 mg), Fluvoxamine (300 mg/150 mg), Paroxetine (50 mg/40 mg), Sertraline (200 mg/100 mg), and Escitalopram (20 mg/20 mg). [source, 2016]
Pharmacologic therapy may include selective serotonin reuptake inhibitor (SSRI) therapy (Citalopram, Sertraline, fluoxetine, dapoxetine or Paroxetine), phosphodiesterase type 5 (PDE5) inhibitor therapy (tadalafil or Sildenafil), topical desensitizing agents (prilocaine or Lidocaine) and other agents (Tramadol or Pindolol). [source, 2016]
Paroxetine is better than fluoxetine, Clomipramine and Sertraline in the treatment of PE. [source, 2016]